Stock data
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT) reported net income of -US$51.04M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$56.89M | -US$51.04M | — |
| 2024 | — | — | -US$54.45M | -US$45.57M | — |
| 2023 | US$2.00M | — | -US$30.74M | -US$27.88M | — |
| 2022 | — | — | -US$31.05M | -US$30.50M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$13.95M | — |
| 2026-03-31 | — | -US$10.65M | — |
| 2025-12-31 | — | -US$9.57M | — |
| 2025-09-30 | — | -US$12.91M | — |
| 2025-06-30 | — | -US$10.39M | — |
| 2025-03-31 | — | -US$18.18M | — |
| 2024-12-31 | — | -US$16.20M | — |
| 2024-09-30 | — | -US$14.62M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.